scholarly journals Utility of antimicrobial combination therapy with break-point checkerboard plate for treatment against multi-drug resistant Pseudomonas aeruginosa

2014 ◽  
Vol 63 (1) ◽  
pp. 53-58
Author(s):  
Tomoko MURASE ◽  
Hideharu HAGIYA ◽  
Yuto HARUKI ◽  
Naoto WATANABE ◽  
Miyako MAKI ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Combination Therapy ◽  
Break Point ◽  
Drug Resistant

scholarly journals Successful treatment of multi-drug resistant Pseudomonas aeruginosa infection using ^|^lsquo;Break-point Checkerboard Plate^|^rsquo;

2012 ◽  
Vol 45 (9) ◽  
pp. 881-887
Author(s):  
Masanori Tamaki ◽  
Shu Wakino ◽  
Yoshihiko Kanno ◽  
Waka Bando ◽  
Koji Hosoya ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Successful Treatment ◽  
Break Point ◽  
Drug Resistant ◽  
Pseudomonas Aeruginosa Infection

scholarly journals Effect of antibiotic combinations by break-point checkerboard plate and disk diffusion method against drug-resistant Pseudomonas aeruginosa

2014 ◽  
Vol 63 (1) ◽  
pp. 18-23
Author(s):  
Hiromi MORISHIGE ◽  
Yoshihito OTSUKA ◽  
Akihiro TOGUCHI ◽  
Masako HIRATA ◽  
Kohei HASHIMOTO ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Break Point ◽  
Disk Diffusion ◽  
Diffusion Method ◽  
Drug Resistant ◽  
Disk Diffusion Method

scholarly journals Polymyxin B in Combination with Antimicrobials LackingIn VitroActivity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections

2015 ◽  
Vol 59 (10) ◽  
pp. 6575-6580 ◽  
Author(s):  
Maria Helena Rigatto ◽  
Fabiane J. Vieira ◽  
Laura C. Antochevis ◽  
Tainá F. Behle ◽  
Natane T. Lopes ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Combination Therapy ◽  
Acinetobacter Baumannii ◽  
Protective Factor ◽  
Polymyxin B ◽  
Apache Ii Score ◽  
Drug Resistant ◽  
Content Type ◽  
Extensively Drug Resistant ◽  
Tract Infections

ABSTRACTThere is no clinical evidence supporting the use of polymyxin B in combination with another antimicrobial for infections caused by extensively drug-resistantAcinetobacter baumanniiorPseudomonas aeruginosaisolates. We developed a cohort study of patients in two intensive care units from teaching hospitals to evaluate treatment with intravenous polymyxin B for ≥48 h for severeA. baumanniiorP. aeruginosainfections. Covariates potentially associated with 30-day mortality were evaluated in a Cox proportional hazards model. A total of 101 patients were included; 33 (32.7%) were treated with polymyxin B in combination with an antimicrobial lackingin vitroactivity and 68 (67.3%) with polymyxin B in monotherapy. The overall 30-day mortality was 59.4% (60 patients), comprising 42.4% (14 of 33) and 67.6% (46 of 68) in combination and monotherapy groups, respectively (P= 0.03). The mortality rates were 18.5/1,000 patient days and 36.4/1,000 patient days in the combination and monotherapy groups, respectively (P= 0.02). Combination therapy was independently associated with lower 30-day mortality (hazard ratio, 0.33; 95% confidence interval, 0.17 to 0.64;P= 0.001). Creatinine clearance of ≥60 ml/min was also a protective factor, while a higher acute physiology and chronic health evaluation (APACHE II) score and polymicrobial infection were associated with increased mortality. The results did not change after adding a propensity score for prescribing combination therapy into the model. The protective effect remained when only combination with β-lactam or carbapenem was considered and in both subgroups of patients: those withA. baumanniiinfection and those with lower respiratory tract infections. To our knowledge, this is the first clinical study to show a benefit of combination over monotherapy with polymyxin B for severe extensively drug-resistantA. baumanniiorP. aeruginosainfections.

Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia

2018 ◽  
Vol 52 (6) ◽  
pp. 828-834 ◽  
Author(s):  
Thana Khawcharoenporn ◽  
Alan Chuncharunee ◽  
Chailat Maluangnon ◽  
Thitiporn Taweesakulvashra ◽  
Pimsiri Tiamsak
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Combination Therapy ◽  
Drug Resistant ◽  
Extensively Drug Resistant
Sign in / Sign up

Export Citation Format

Share Document